A new technology may allow patients to recover vision for conditions that were previously thought irreversible ...

Kodiak Sciences Inc. announced at the recent American Academy of Ophthalmology meetings that intraocular interleukin-6 inhibition in Phase 3 clinical trials delivered meaningful improvement in vision ...

Kodiak Sciences Inc. , today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third ...

Treatment for geographic atrophy is more likely to be acceptable to patients if they believe it may improve vision, a study shows.

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to ...

CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for ...